Solid Tumor Clinical Trials

USOR #20186

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (BO41932).

This trial is for patients with solid tumors that are advanced and unresectable or metastatic disease.

Cohort A: ROS1 fusion

• NSCLC excluded

Cohort B: NTRK 1/2/3 fusion

• Prior treatment with NTRK inhibitors Excluded

Cohort C ALK fusion-positive tumors

• NSCLC and neuroblastoma excluded. Prior treatment with a ALK inhibitor excluded